0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Pseudorabies Virus Vaccine Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-14B9979
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Pseudorabies Virus Vaccine Market Insights Forecast to 2028
BUY CHAPTERS

Global Pseudorabies Virus Vaccine Market Research Report 2024

Code: QYRE-Auto-14B9979
Report
February 2024
Pages:111
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Pseudorabies Virus Vaccine Market

Porcine pseudorabies is an acute infectious disease of pigs caused by Pseudorabies virus (PrV). The disease is fulminant in pigs. It can cause abortion of pregnant sows, stillbirth, infertility of boars, death of a large number of newborn piglets, difficulty in breathing of fattening pigs, and stagnant growth. It is one of the major infectious diseases that harm the global pig industry.
The global Pseudorabies Virus Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pseudorabies Virus Vaccine include Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd. and CHINA ANIMAL HUSBANDRY INDUSTRY, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pseudorabies Virus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pseudorabies Virus Vaccine.

Report Scope

The Pseudorabies Virus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pseudorabies Virus Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pseudorabies Virus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Pseudorabies Virus Vaccine Market Report

Report Metric Details
Report Name Pseudorabies Virus Vaccine Market
Segment by Type
  • Inactivated Vaccine
  • Naturally Deficient Attenuated Vaccine
  • Genetic Engineering Vaccine
Segment by Application
  • Government Tender
  • Market Sales
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd., CHINA ANIMAL HUSBANDRY INDUSTRY, Sichuan Huashen, Haley, Tianbang, Dabei Nong, Harvey, Preh Bio, Jiangsu Nannong High-Tech Co., Guangxi Liyuan Biological Co., Ltd., Jilin Zhengye Bioengineering Group, Jilin Heyuan Biological Engineering Co., Ltd., Huapai Biological Engineering Group Co., Ltd., Beijing Xinde Weite Technology Co., Ltd., Beijing Veterinary Biopharmaceutical Factory, Qilu Animal Health Products Co., Ltd., Shanxi Longkel Bio-Pharmaceutical Co., Ltd., Yunnan Biopharmaceutical Co., Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd., Liaoning Yikang Biological Co., Ltd., Shanghui Huahong Biological Engineering Co., Ltd., Sichuan Hailinge Biological Pharmaceutical Co., Ltd., Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Pseudorabies Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Pseudorabies Virus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Pseudorabies Virus Vaccine Market report?

Ans: The main players in the Pseudorabies Virus Vaccine Market are Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd., CHINA ANIMAL HUSBANDRY INDUSTRY, Sichuan Huashen, Haley, Tianbang, Dabei Nong, Harvey, Preh Bio, Jiangsu Nannong High-Tech Co., Guangxi Liyuan Biological Co., Ltd., Jilin Zhengye Bioengineering Group, Jilin Heyuan Biological Engineering Co., Ltd., Huapai Biological Engineering Group Co., Ltd., Beijing Xinde Weite Technology Co., Ltd., Beijing Veterinary Biopharmaceutical Factory, Qilu Animal Health Products Co., Ltd., Shanxi Longkel Bio-Pharmaceutical Co., Ltd., Yunnan Biopharmaceutical Co., Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd., Liaoning Yikang Biological Co., Ltd., Shanghui Huahong Biological Engineering Co., Ltd., Sichuan Hailinge Biological Pharmaceutical Co., Ltd., Guangdong Yongshun Biological Pharmaceutical Co., Ltd.

What are the Application segmentation covered in the Pseudorabies Virus Vaccine Market report?

Ans: The Applications covered in the Pseudorabies Virus Vaccine Market report are Government Tender, Market Sales

What are the Type segmentation covered in the Pseudorabies Virus Vaccine Market report?

Ans: The Types covered in the Pseudorabies Virus Vaccine Market report are Inactivated Vaccine, Naturally Deficient Attenuated Vaccine, Genetic Engineering Vaccine

1 Pseudorabies Virus Vaccine Market Overview
1.1 Product Overview and Scope of Pseudorabies Virus Vaccine
1.2 Pseudorabies Virus Vaccine Segment by Type
1.2.1 Global Pseudorabies Virus Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Inactivated Vaccine
1.2.3 Naturally Deficient Attenuated Vaccine
1.2.4 Genetic Engineering Vaccine
1.3 Pseudorabies Virus Vaccine Segment by Application
1.3.1 Global Pseudorabies Virus Vaccine Market Value by Application: (2024-2030)
1.3.2 Government Tender
1.3.3 Market Sales
1.4 Global Pseudorabies Virus Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pseudorabies Virus Vaccine Revenue 2019-2030
1.4.2 Global Pseudorabies Virus Vaccine Sales 2019-2030
1.4.3 Global Pseudorabies Virus Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pseudorabies Virus Vaccine Market Competition by Manufacturers
2.1 Global Pseudorabies Virus Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pseudorabies Virus Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pseudorabies Virus Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Pseudorabies Virus Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pseudorabies Virus Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pseudorabies Virus Vaccine, Product Type & Application
2.7 Pseudorabies Virus Vaccine Market Competitive Situation and Trends
2.7.1 Pseudorabies Virus Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pseudorabies Virus Vaccine Players Market Share by Revenue
2.7.3 Global Pseudorabies Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pseudorabies Virus Vaccine Retrospective Market Scenario by Region
3.1 Global Pseudorabies Virus Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pseudorabies Virus Vaccine Global Pseudorabies Virus Vaccine Sales by Region: 2019-2030
3.2.1 Global Pseudorabies Virus Vaccine Sales by Region: 2019-2024
3.2.2 Global Pseudorabies Virus Vaccine Sales by Region: 2025-2030
3.3 Global Pseudorabies Virus Vaccine Global Pseudorabies Virus Vaccine Revenue by Region: 2019-2030
3.3.1 Global Pseudorabies Virus Vaccine Revenue by Region: 2019-2024
3.3.2 Global Pseudorabies Virus Vaccine Revenue by Region: 2025-2030
3.4 North America Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.4.1 North America Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.4.3 North America Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.5.1 Europe Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.5.3 Europe Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.7.1 Latin America Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pseudorabies Virus Vaccine Sales by Type (2019-2030)
4.1.1 Global Pseudorabies Virus Vaccine Sales by Type (2019-2024)
4.1.2 Global Pseudorabies Virus Vaccine Sales by Type (2025-2030)
4.1.3 Global Pseudorabies Virus Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Pseudorabies Virus Vaccine Revenue by Type (2019-2030)
4.2.1 Global Pseudorabies Virus Vaccine Revenue by Type (2019-2024)
4.2.2 Global Pseudorabies Virus Vaccine Revenue by Type (2025-2030)
4.2.3 Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Pseudorabies Virus Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pseudorabies Virus Vaccine Sales by Application (2019-2030)
5.1.1 Global Pseudorabies Virus Vaccine Sales by Application (2019-2024)
5.1.2 Global Pseudorabies Virus Vaccine Sales by Application (2025-2030)
5.1.3 Global Pseudorabies Virus Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Pseudorabies Virus Vaccine Revenue by Application (2019-2030)
5.2.1 Global Pseudorabies Virus Vaccine Revenue by Application (2019-2024)
5.2.2 Global Pseudorabies Virus Vaccine Revenue by Application (2025-2030)
5.2.3 Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Pseudorabies Virus Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Pseudorabies Virus Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Merial Limited
6.2.1 Merial Limited Corporation Information
6.2.2 Merial Limited Description and Business Overview
6.2.3 Merial Limited Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merial Limited Pseudorabies Virus Vaccine Product Portfolio
6.2.5 Merial Limited Recent Developments/Updates
6.3 Boehringer Ingelheim Animal Health (USA) Co., Ltd.
6.3.1 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Corporation Information
6.3.2 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Description and Business Overview
6.3.3 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Recent Developments/Updates
6.4 Zoetis
6.4.1 Zoetis Corporation Information
6.4.2 Zoetis Description and Business Overview
6.4.3 Zoetis Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zoetis Pseudorabies Virus Vaccine Product Portfolio
6.4.5 Zoetis Recent Developments/Updates
6.5 Hipra
6.5.1 Hipra Corporation Information
6.5.2 Hipra Description and Business Overview
6.5.3 Hipra Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hipra Pseudorabies Virus Vaccine Product Portfolio
6.5.5 Hipra Recent Developments/Updates
6.6 Anhui Divinity Biological Products
6.6.1 Anhui Divinity Biological Products Corporation Information
6.6.2 Anhui Divinity Biological Products Description and Business Overview
6.6.3 Anhui Divinity Biological Products Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Anhui Divinity Biological Products Pseudorabies Virus Vaccine Product Portfolio
6.6.5 Anhui Divinity Biological Products Recent Developments/Updates
6.7 Wuhan Keqian Biological Co., Ltd.
6.6.1 Wuhan Keqian Biological Co., Ltd. Corporation Information
6.6.2 Wuhan Keqian Biological Co., Ltd. Description and Business Overview
6.6.3 Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.7.5 Wuhan Keqian Biological Co., Ltd. Recent Developments/Updates
6.8 China Biotechnology Co., Ltd.
6.8.1 China Biotechnology Co., Ltd. Corporation Information
6.8.2 China Biotechnology Co., Ltd. Description and Business Overview
6.8.3 China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.8.5 China Biotechnology Co., Ltd. Recent Developments/Updates
6.9 CHINA ANIMAL HUSBANDRY INDUSTRY
6.9.1 CHINA ANIMAL HUSBANDRY INDUSTRY Corporation Information
6.9.2 CHINA ANIMAL HUSBANDRY INDUSTRY Description and Business Overview
6.9.3 CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Product Portfolio
6.9.5 CHINA ANIMAL HUSBANDRY INDUSTRY Recent Developments/Updates
6.10 Sichuan Huashen
6.10.1 Sichuan Huashen Corporation Information
6.10.2 Sichuan Huashen Description and Business Overview
6.10.3 Sichuan Huashen Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sichuan Huashen Pseudorabies Virus Vaccine Product Portfolio
6.10.5 Sichuan Huashen Recent Developments/Updates
6.11 Haley
6.11.1 Haley Corporation Information
6.11.2 Haley Pseudorabies Virus Vaccine Description and Business Overview
6.11.3 Haley Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Haley Pseudorabies Virus Vaccine Product Portfolio
6.11.5 Haley Recent Developments/Updates
6.12 Tianbang
6.12.1 Tianbang Corporation Information
6.12.2 Tianbang Pseudorabies Virus Vaccine Description and Business Overview
6.12.3 Tianbang Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Tianbang Pseudorabies Virus Vaccine Product Portfolio
6.12.5 Tianbang Recent Developments/Updates
6.13 Dabei Nong
6.13.1 Dabei Nong Corporation Information
6.13.2 Dabei Nong Pseudorabies Virus Vaccine Description and Business Overview
6.13.3 Dabei Nong Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Dabei Nong Pseudorabies Virus Vaccine Product Portfolio
6.13.5 Dabei Nong Recent Developments/Updates
6.14 Harvey
6.14.1 Harvey Corporation Information
6.14.2 Harvey Pseudorabies Virus Vaccine Description and Business Overview
6.14.3 Harvey Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Harvey Pseudorabies Virus Vaccine Product Portfolio
6.14.5 Harvey Recent Developments/Updates
6.15 Preh Bio
6.15.1 Preh Bio Corporation Information
6.15.2 Preh Bio Pseudorabies Virus Vaccine Description and Business Overview
6.15.3 Preh Bio Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Preh Bio Pseudorabies Virus Vaccine Product Portfolio
6.15.5 Preh Bio Recent Developments/Updates
6.16 Jiangsu Nannong High-Tech Co.
6.16.1 Jiangsu Nannong High-Tech Co. Corporation Information
6.16.2 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Description and Business Overview
6.16.3 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Product Portfolio
6.16.5 Jiangsu Nannong High-Tech Co. Recent Developments/Updates
6.17 Guangxi Liyuan Biological Co., Ltd.
6.17.1 Guangxi Liyuan Biological Co., Ltd. Corporation Information
6.17.2 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.17.3 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.17.5 Guangxi Liyuan Biological Co., Ltd. Recent Developments/Updates
6.18 Jilin Zhengye Bioengineering Group
6.18.1 Jilin Zhengye Bioengineering Group Corporation Information
6.18.2 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Description and Business Overview
6.18.3 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Product Portfolio
6.18.5 Jilin Zhengye Bioengineering Group Recent Developments/Updates
6.19 Jilin Heyuan Biological Engineering Co., Ltd.
6.19.1 Jilin Heyuan Biological Engineering Co., Ltd. Corporation Information
6.19.2 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.19.3 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.19.5 Jilin Heyuan Biological Engineering Co., Ltd. Recent Developments/Updates
6.20 Huapai Biological Engineering Group Co., Ltd.
6.20.1 Huapai Biological Engineering Group Co., Ltd. Corporation Information
6.20.2 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.20.3 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.20.5 Huapai Biological Engineering Group Co., Ltd. Recent Developments/Updates
6.21 Beijing Xinde Weite Technology Co., Ltd.
6.21.1 Beijing Xinde Weite Technology Co., Ltd. Corporation Information
6.21.2 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.21.3 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.21.5 Beijing Xinde Weite Technology Co., Ltd. Recent Developments/Updates
6.22 Beijing Veterinary Biopharmaceutical Factory
6.22.1 Beijing Veterinary Biopharmaceutical Factory Corporation Information
6.22.2 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Description and Business Overview
6.22.3 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Product Portfolio
6.22.5 Beijing Veterinary Biopharmaceutical Factory Recent Developments/Updates
6.23 Qilu Animal Health Products Co., Ltd.
6.23.1 Qilu Animal Health Products Co., Ltd. Corporation Information
6.23.2 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.23.3 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.23.5 Qilu Animal Health Products Co., Ltd. Recent Developments/Updates
6.24 Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
6.24.1 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Corporation Information
6.24.2 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.24.3 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.24.5 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Recent Developments/Updates
6.25 Yunnan Biopharmaceutical Co.
6.25.1 Yunnan Biopharmaceutical Co. Corporation Information
6.25.2 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Description and Business Overview
6.25.3 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Product Portfolio
6.25.5 Yunnan Biopharmaceutical Co. Recent Developments/Updates
6.26 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
6.26.1 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Corporation Information
6.26.2 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.26.3 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.26.5 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
6.27 Liaoning Yikang Biological Co., Ltd.
6.27.1 Liaoning Yikang Biological Co., Ltd. Corporation Information
6.27.2 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.27.3 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.27.4 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.27.5 Liaoning Yikang Biological Co., Ltd. Recent Developments/Updates
6.28 Shanghui Huahong Biological Engineering Co., Ltd.
6.28.1 Shanghui Huahong Biological Engineering Co., Ltd. Corporation Information
6.28.2 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.28.3 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.28.4 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.28.5 Shanghui Huahong Biological Engineering Co., Ltd. Recent Developments/Updates
6.29 Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
6.29.1 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Corporation Information
6.29.2 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.29.3 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.29.4 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.29.5 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
6.30 Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
6.30.1 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Corporation Information
6.30.2 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.30.3 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.30.4 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.30.5 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pseudorabies Virus Vaccine Industry Chain Analysis
7.2 Pseudorabies Virus Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pseudorabies Virus Vaccine Production Mode & Process
7.4 Pseudorabies Virus Vaccine Sales and Marketing
7.4.1 Pseudorabies Virus Vaccine Sales Channels
7.4.2 Pseudorabies Virus Vaccine Distributors
7.5 Pseudorabies Virus Vaccine Customers
8 Pseudorabies Virus Vaccine Market Dynamics
8.1 Pseudorabies Virus Vaccine Industry Trends
8.2 Pseudorabies Virus Vaccine Market Drivers
8.3 Pseudorabies Virus Vaccine Market Challenges
8.4 Pseudorabies Virus Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Pseudorabies Virus Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Pseudorabies Virus Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Pseudorabies Virus Vaccine Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Pseudorabies Virus Vaccine Sales (M Doses) of Key Manufacturers (2019-2024)
    Table 5. Global Pseudorabies Virus Vaccine Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Pseudorabies Virus Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Pseudorabies Virus Vaccine Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Pseudorabies Virus Vaccine Average Price (USD/Doses) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Pseudorabies Virus Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Pseudorabies Virus Vaccine, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Pseudorabies Virus Vaccine, Product Type & Application
    Table 12. Global Key Manufacturers of Pseudorabies Virus Vaccine, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Pseudorabies Virus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pseudorabies Virus Vaccine as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Pseudorabies Virus Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Pseudorabies Virus Vaccine Sales by Region (2019-2024) & (M Doses)
    Table 18. Global Pseudorabies Virus Vaccine Sales Market Share by Region (2019-2024)
    Table 19. Global Pseudorabies Virus Vaccine Sales by Region (2025-2030) & (M Doses)
    Table 20. Global Pseudorabies Virus Vaccine Sales Market Share by Region (2025-2030)
    Table 21. Global Pseudorabies Virus Vaccine Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Pseudorabies Virus Vaccine Revenue Market Share by Region (2019-2024)
    Table 23. Global Pseudorabies Virus Vaccine Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Pseudorabies Virus Vaccine Revenue Market Share by Region (2025-2030)
    Table 25. North America Pseudorabies Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Pseudorabies Virus Vaccine Sales by Country (2019-2024) & (M Doses)
    Table 27. North America Pseudorabies Virus Vaccine Sales by Country (2025-2030) & (M Doses)
    Table 28. North America Pseudorabies Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Pseudorabies Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Pseudorabies Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Pseudorabies Virus Vaccine Sales by Country (2019-2024) & (M Doses)
    Table 32. Europe Pseudorabies Virus Vaccine Sales by Country (2025-2030) & (M Doses)
    Table 33. Europe Pseudorabies Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Pseudorabies Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Pseudorabies Virus Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Pseudorabies Virus Vaccine Sales by Region (2019-2024) & (M Doses)
    Table 37. Asia Pacific Pseudorabies Virus Vaccine Sales by Region (2025-2030) & (M Doses)
    Table 38. Asia Pacific Pseudorabies Virus Vaccine Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Pseudorabies Virus Vaccine Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Pseudorabies Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Pseudorabies Virus Vaccine Sales by Country (2019-2024) & (M Doses)
    Table 42. Latin America Pseudorabies Virus Vaccine Sales by Country (2025-2030) & (M Doses)
    Table 43. Latin America Pseudorabies Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Pseudorabies Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Pseudorabies Virus Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2019-2024) & (M Doses)
    Table 47. Middle East & Africa Pseudorabies Virus Vaccine Sales by Country (2025-2030) & (M Doses)
    Table 48. Middle East & Africa Pseudorabies Virus Vaccine Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Pseudorabies Virus Vaccine Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Pseudorabies Virus Vaccine Sales (M Doses) by Type (2019-2024)
    Table 51. Global Pseudorabies Virus Vaccine Sales (M Doses) by Type (2025-2030)
    Table 52. Global Pseudorabies Virus Vaccine Sales Market Share by Type (2019-2024)
    Table 53. Global Pseudorabies Virus Vaccine Sales Market Share by Type (2025-2030)
    Table 54. Global Pseudorabies Virus Vaccine Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Pseudorabies Virus Vaccine Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2019-2024)
    Table 57. Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2025-2030)
    Table 58. Global Pseudorabies Virus Vaccine Price (USD/Doses) by Type (2019-2024)
    Table 59. Global Pseudorabies Virus Vaccine Price (USD/Doses) by Type (2025-2030)
    Table 60. Global Pseudorabies Virus Vaccine Sales (M Doses) by Application (2019-2024)
    Table 61. Global Pseudorabies Virus Vaccine Sales (M Doses) by Application (2025-2030)
    Table 62. Global Pseudorabies Virus Vaccine Sales Market Share by Application (2019-2024)
    Table 63. Global Pseudorabies Virus Vaccine Sales Market Share by Application (2025-2030)
    Table 64. Global Pseudorabies Virus Vaccine Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Pseudorabies Virus Vaccine Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2019-2024)
    Table 67. Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2025-2030)
    Table 68. Global Pseudorabies Virus Vaccine Price (USD/Doses) by Application (2019-2024)
    Table 69. Global Pseudorabies Virus Vaccine Price (USD/Doses) by Application (2025-2030)
    Table 70. Merck Corporation Information
    Table 71. Merck Description and Business Overview
    Table 72. Merck Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 73. Merck Pseudorabies Virus Vaccine Product
    Table 74. Merck Recent Developments/Updates
    Table 75. Merial Limited Corporation Information
    Table 76. Merial Limited Description and Business Overview
    Table 77. Merial Limited Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 78. Merial Limited Pseudorabies Virus Vaccine Product
    Table 79. Merial Limited Recent Developments/Updates
    Table 80. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Corporation Information
    Table 81. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Description and Business Overview
    Table 82. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 83. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 84. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Recent Developments/Updates
    Table 85. Zoetis Corporation Information
    Table 86. Zoetis Description and Business Overview
    Table 87. Zoetis Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 88. Zoetis Pseudorabies Virus Vaccine Product
    Table 89. Zoetis Recent Developments/Updates
    Table 90. Hipra Corporation Information
    Table 91. Hipra Description and Business Overview
    Table 92. Hipra Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 93. Hipra Pseudorabies Virus Vaccine Product
    Table 94. Hipra Recent Developments/Updates
    Table 95. Anhui Divinity Biological Products Corporation Information
    Table 96. Anhui Divinity Biological Products Description and Business Overview
    Table 97. Anhui Divinity Biological Products Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 98. Anhui Divinity Biological Products Pseudorabies Virus Vaccine Product
    Table 99. Anhui Divinity Biological Products Recent Developments/Updates
    Table 100. Wuhan Keqian Biological Co., Ltd. Corporation Information
    Table 101. Wuhan Keqian Biological Co., Ltd. Description and Business Overview
    Table 102. Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 103. Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 104. Wuhan Keqian Biological Co., Ltd. Recent Developments/Updates
    Table 105. China Biotechnology Co., Ltd. Corporation Information
    Table 106. China Biotechnology Co., Ltd. Description and Business Overview
    Table 107. China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 108. China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 109. China Biotechnology Co., Ltd. Recent Developments/Updates
    Table 110. CHINA ANIMAL HUSBANDRY INDUSTRY Corporation Information
    Table 111. CHINA ANIMAL HUSBANDRY INDUSTRY Description and Business Overview
    Table 112. CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 113. CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Product
    Table 114. CHINA ANIMAL HUSBANDRY INDUSTRY Recent Developments/Updates
    Table 115. Sichuan Huashen Corporation Information
    Table 116. Sichuan Huashen Description and Business Overview
    Table 117. Sichuan Huashen Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 118. Sichuan Huashen Pseudorabies Virus Vaccine Product
    Table 119. Sichuan Huashen Recent Developments/Updates
    Table 120. Haley Corporation Information
    Table 121. Haley Description and Business Overview
    Table 122. Haley Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 123. Haley Pseudorabies Virus Vaccine Product
    Table 124. Haley Recent Developments/Updates
    Table 125. Tianbang Corporation Information
    Table 126. Tianbang Description and Business Overview
    Table 127. Tianbang Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 128. Tianbang Pseudorabies Virus Vaccine Product
    Table 129. Tianbang Recent Developments/Updates
    Table 130. Dabei Nong Corporation Information
    Table 131. Dabei Nong Description and Business Overview
    Table 132. Dabei Nong Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 133. Dabei Nong Pseudorabies Virus Vaccine Product
    Table 134. Dabei Nong Recent Developments/Updates
    Table 135. Harvey Corporation Information
    Table 136. Harvey Description and Business Overview
    Table 137. Harvey Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 138. Harvey Pseudorabies Virus Vaccine Product
    Table 139. Harvey Recent Developments/Updates
    Table 140. Preh Bio Corporation Information
    Table 141. Preh Bio Description and Business Overview
    Table 142. Preh Bio Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 143. Preh Bio Pseudorabies Virus Vaccine Product
    Table 144. Preh Bio Recent Developments/Updates
    Table 145. Jiangsu Nannong High-Tech Co. Corporation Information
    Table 146. Jiangsu Nannong High-Tech Co. Description and Business Overview
    Table 147. Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 148. Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Product
    Table 149. Jiangsu Nannong High-Tech Co. Recent Developments/Updates
    Table 150. Guangxi Liyuan Biological Co., Ltd. Corporation Information
    Table 151. Guangxi Liyuan Biological Co., Ltd. Description and Business Overview
    Table 152. Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 153. Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 154. Guangxi Liyuan Biological Co., Ltd. Recent Developments/Updates
    Table 155. Jilin Zhengye Bioengineering Group Corporation Information
    Table 156. Jilin Zhengye Bioengineering Group Description and Business Overview
    Table 157. Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 158. Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Product
    Table 159. Jilin Zhengye Bioengineering Group Recent Developments/Updates
    Table 160. Jilin Heyuan Biological Engineering Co., Ltd. Corporation Information
    Table 161. Jilin Heyuan Biological Engineering Co., Ltd. Description and Business Overview
    Table 162. Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 163. Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 164. Jilin Heyuan Biological Engineering Co., Ltd. Recent Developments/Updates
    Table 165. Huapai Biological Engineering Group Co., Ltd. Corporation Information
    Table 166. Huapai Biological Engineering Group Co., Ltd. Description and Business Overview
    Table 167. Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 168. Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 169. Huapai Biological Engineering Group Co., Ltd. Recent Developments/Updates
    Table 170. Beijing Xinde Weite Technology Co., Ltd. Corporation Information
    Table 171. Beijing Xinde Weite Technology Co., Ltd. Description and Business Overview
    Table 172. Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 173. Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 174. Beijing Xinde Weite Technology Co., Ltd. Recent Developments/Updates
    Table 175. Beijing Veterinary Biopharmaceutical Factory Corporation Information
    Table 176. Beijing Veterinary Biopharmaceutical Factory Description and Business Overview
    Table 177. Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 178. Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Product
    Table 179. Beijing Veterinary Biopharmaceutical Factory Recent Developments/Updates
    Table 180. Qilu Animal Health Products Co., Ltd. Corporation Information
    Table 181. Qilu Animal Health Products Co., Ltd. Description and Business Overview
    Table 182. Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 183. Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 184. Qilu Animal Health Products Co., Ltd. Recent Developments/Updates
    Table 185. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Corporation Information
    Table 186. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Description and Business Overview
    Table 187. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 188. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 189. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Recent Developments/Updates
    Table 190. Yunnan Biopharmaceutical Co. Corporation Information
    Table 191. Yunnan Biopharmaceutical Co. Description and Business Overview
    Table 192. Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 193. Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Product
    Table 194. Yunnan Biopharmaceutical Co. Recent Developments/Updates
    Table 195. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Corporation Information
    Table 196. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Description and Business Overview
    Table 197. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 198. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 199. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
    Table 200. Liaoning Yikang Biological Co., Ltd. Corporation Information
    Table 201. Liaoning Yikang Biological Co., Ltd. Description and Business Overview
    Table 202. Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 203. Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 204. Liaoning Yikang Biological Co., Ltd. Recent Developments/Updates
    Table 205. Shanghui Huahong Biological Engineering Co., Ltd. Corporation Information
    Table 206. Shanghui Huahong Biological Engineering Co., Ltd. Description and Business Overview
    Table 207. Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 208. Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 209. Shanghui Huahong Biological Engineering Co., Ltd. Recent Developments/Updates
    Table 210. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Corporation Information
    Table 211. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Description and Business Overview
    Table 212. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 213. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 214. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
    Table 215. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Corporation Information
    Table 216. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Description and Business Overview
    Table 217. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales (M Doses), Revenue (US$ Million), Price (USD/Doses) and Gross Margin (2019-2024)
    Table 218. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product
    Table 219. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
    Table 220. Key Raw Materials Lists
    Table 221. Raw Materials Key Suppliers Lists
    Table 222. Pseudorabies Virus Vaccine Distributors List
    Table 223. Pseudorabies Virus Vaccine Customers List
    Table 224. Pseudorabies Virus Vaccine Market Trends
    Table 225. Pseudorabies Virus Vaccine Market Drivers
    Table 226. Pseudorabies Virus Vaccine Market Challenges
    Table 227. Pseudorabies Virus Vaccine Market Restraints
    Table 228. Research Programs/Design for This Report
    Table 229. Key Data Information from Secondary Sources
    Table 230. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Pseudorabies Virus Vaccine
    Figure 2. Global Pseudorabies Virus Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Pseudorabies Virus Vaccine Market Share by Type in 2023 & 2030
    Figure 4. Inactivated Vaccine Product Picture
    Figure 5. Naturally Deficient Attenuated Vaccine Product Picture
    Figure 6. Genetic Engineering Vaccine Product Picture
    Figure 7. Global Pseudorabies Virus Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Pseudorabies Virus Vaccine Market Share by Application in 2023 & 2030
    Figure 9. Government Tender
    Figure 10. Market Sales
    Figure 11. Global Pseudorabies Virus Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 12. Global Pseudorabies Virus Vaccine Market Size (2019-2030) & (US$ Million)
    Figure 13. Global Pseudorabies Virus Vaccine Sales (2019-2030) & (M Doses)
    Figure 14. Global Pseudorabies Virus Vaccine Average Price (USD/Doses) & (2019-2030)
    Figure 15. Pseudorabies Virus Vaccine Report Years Considered
    Figure 16. Pseudorabies Virus Vaccine Sales Share by Manufacturers in 2023
    Figure 17. Global Pseudorabies Virus Vaccine Revenue Share by Manufacturers in 2023
    Figure 18. The Global 5 and 10 Largest Pseudorabies Virus Vaccine Players: Market Share by Revenue in 2023
    Figure 19. Pseudorabies Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 20. Global Pseudorabies Virus Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 21. North America Pseudorabies Virus Vaccine Sales Market Share by Country (2019-2030)
    Figure 22. North America Pseudorabies Virus Vaccine Revenue Market Share by Country (2019-2030)
    Figure 23. U.S. Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 24. Canada Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Europe Pseudorabies Virus Vaccine Sales Market Share by Country (2019-2030)
    Figure 26. Europe Pseudorabies Virus Vaccine Revenue Market Share by Country (2019-2030)
    Figure 27. Germany Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 28. France Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. U.K. Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. Italy Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Russia Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Asia Pacific Pseudorabies Virus Vaccine Sales Market Share by Region (2019-2030)
    Figure 33. Asia Pacific Pseudorabies Virus Vaccine Revenue Market Share by Region (2019-2030)
    Figure 34. China Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 35. Japan Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. South Korea Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. India Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. Australia Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Taiwan Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Indonesia Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Thailand Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Malaysia Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Philippines Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Latin America Pseudorabies Virus Vaccine Sales Market Share by Country (2019-2030)
    Figure 45. Latin America Pseudorabies Virus Vaccine Revenue Market Share by Country (2019-2030)
    Figure 46. Mexico Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Brazil Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Argentina Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Middle East & Africa Pseudorabies Virus Vaccine Sales Market Share by Country (2019-2030)
    Figure 50. Middle East & Africa Pseudorabies Virus Vaccine Revenue Market Share by Country (2019-2030)
    Figure 51. Turkey Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 52. Saudi Arabia Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. U.A.E Pseudorabies Virus Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. Global Sales Market Share of Pseudorabies Virus Vaccine by Type (2019-2030)
    Figure 55. Global Revenue Market Share of Pseudorabies Virus Vaccine by Type (2019-2030)
    Figure 56. Global Pseudorabies Virus Vaccine Price (USD/Doses) by Type (2019-2030)
    Figure 57. Global Sales Market Share of Pseudorabies Virus Vaccine by Application (2019-2030)
    Figure 58. Global Revenue Market Share of Pseudorabies Virus Vaccine by Application (2019-2030)
    Figure 59. Global Pseudorabies Virus Vaccine Price (USD/Doses) by Application (2019-2030)
    Figure 60. Pseudorabies Virus Vaccine Value Chain
    Figure 61. Pseudorabies Virus Vaccine Production Process
    Figure 62. Channels of Distribution (Direct Vs Distribution)
    Figure 63. Distributors Profiles
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS